Understanding and targeting cancer stemness and immune suppression in advanced gastric cancer
Official title: Molecular dissecting and targeting YAP1 mediated cancer stemness and immune suppression in advanced gastric adenocarcinoma
Funded at Coriell Institute for Medical Research · NIH-10933008 · Data updated 2026-11-12
This study is looking at how a protein called YAP1 affects advanced stomach cancer, especially in patients with cancer that has spread to the lining of the abdomen, to find new ways to treat this tough condition and help improve outcomes for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Coriell Institute for Medical Research NIH-funded |
| Lab location | 1 site (Camden, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $420,169 |
| NIH project number | 5R01CA269685-03 |
| Project ID | NIH-10933008 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with advanced gastric adenocarcinoma, particularly those experiencing peritoneal carcinomatosis.
✕Less likely to help
Patients with early-stage gastric cancer or those without peritoneal carcinomatosis may not benefit from this research.
What this research studies
This research investigates the role of YAP1 in advanced gastric adenocarcinoma, particularly focusing on its impact on cancer stemness and immune suppression in patients with peritoneal carcinomatosis. By analyzing patient-derived specimens, the study aims to uncover the molecular mechanisms that contribute to the aggressive nature of this cancer and its resistance to treatment. The researchers will utilize advanced techniques, including single-cell RNA sequencing, to identify potential therapeutic targets that could improve patient outcomes. The ultimate goal is to develop novel treatments that can effectively combat this challenging condition.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly improve survival rates and quality of life for patients with advanced gastric adenocarcinoma.
How similar studies have gone: While the specific approach of targeting YAP1 in this context is novel, similar research has shown promise in other cancer types, indicating potential for success.
Where this research is happening
-
Coriell Institute for Medical Research
Camden, United States Active
Researchers
- Principal investigator: Song, Shumei — Coriell Institute for Medical Research
- Study coordinator: Song, Shumei
Related research
Other NIH-funded projects on the same topics.
-
Understanding how CDH1 loss drives aggressive stomach cancer and how to target it
Researchers are studying why certain advanced stomach cancers grow and spread, with a focus on CDH1 inactivation and related pathways to find ways to improve treatment for patients.
-
Common stem cell origin in Barrett's-related cancers
This research looks at whether a single stem cell type drives both esophageal and gastric cancers that arise from Barrett’s esophagus, with the aim of finding shared clues to prevent or treat these diseases.
-
Shared stem cell source for lower esophagus and upper stomach cancers
This project looks at whether the same type of stem cell drives cancers that start in Barrett's esophagus and the nearby stomach, with implications for people who have Barrett's esophagus or gastric intestinal metaplasia.
-
Targeting YAP1 to stop stomach cancer spread and immune suppression
This project looks for ways to block a protein called YAP1 to help people with advanced stomach (gastric) cancer that has spread to the lining of the abdomen.
-
Understanding how certain genetic changes lead to advanced stomach cancer
This study is looking into how a specific gene called CDH1 affects the growth of advanced stomach cancer, with the hope of finding better treatment options tailored to different types of the disease, so that patients can receive care that works best for them.
-
Investigating the common origin of esophageal and gastric cancers
This study is looking into how esophageal adenocarcinoma and intestinal gastric cancer start and develop, aiming to find early warning signs and better treatments for people dealing with these cancers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.